BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29368591)

  • 21. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b.
    Verez-Bencomo V; Fernández-Santana V; Hardy E; Toledo ME; Rodríguez MC; Heynngnezz L; Rodriguez A; Baly A; Herrera L; Izquierdo M; Villar A; Valdés Y; Cosme K; Deler ML; Montane M; Garcia E; Ramos A; Aguilar A; Medina E; Toraño G; Sosa I; Hernandez I; Martínez R; Muzachio A; Carmenates A; Costa L; Cardoso F; Campa C; Diaz M; Roy R
    Science; 2004 Jul; 305(5683):522-5. PubMed ID: 15273395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nationwide population-based surveillance of invasive Haemophilus influenzae diseases in children after the introduction of the Haemophilus influenzae type b vaccine in Japan.
    Suga S; Ishiwada N; Sasaki Y; Akeda H; Nishi J; Okada K; Fujieda M; Oda M; Asada K; Nakano T; Saitoh A; Hosoya M; Togashi T; Matsuoka M; Kimura K; Shibayama K
    Vaccine; 2018 Sep; 36(38):5678-5684. PubMed ID: 30122645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
    Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
    Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine.
    Kurikka S; Käyhty H; Peltola H; Saarinen L; Eskola J; Mäkelä PH
    Pediatrics; 1995 Jun; 95(6):815-22. PubMed ID: 7761204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.
    Bryant KA; Marshall GS
    Expert Rev Vaccines; 2011 Jul; 10(7):941-50. PubMed ID: 21806393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger.
    Campagne G; Garba A; Schuchat A; Boulanger D; Plikaytis BD; Ousseini M; Chippaux JP
    Am J Trop Med Hyg; 1998 Nov; 59(5):837-42. PubMed ID: 9840608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age.
    Marshall GS; Blatter M; Marchant C; Aris E; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2013 Jun; 32(6):662-8. PubMed ID: 23340564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates.
    Schneerson R; Robbins JB; Chu C; Sutton A; Vann W; Vickers JC; London WT; Curfman B; Hardegree MC; Shiloach J
    Infect Immun; 1984 Sep; 45(3):582-91. PubMed ID: 6332076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MenHibrix: a new combination meningococcal vaccine for infants and toddlers.
    Hale SF; Camaione L; Lomaestro BM
    Ann Pharmacother; 2014 Mar; 48(3):404-11. PubMed ID: 24353263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination.
    Goldblatt D; Richmond P; Millard E; Thornton C; Miller E
    J Infect Dis; 1999 Aug; 180(2):538-41. PubMed ID: 10395878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological characterization of conjugated Haemophilus influenzae type b vaccine failure in infants.
    Breukels MA; Spanjaard L; Sanders LA; Rijkers GT
    Clin Infect Dis; 2001 Jun; 32(12):1700-5. PubMed ID: 11360210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
    Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.
    Chu C; Schneerson R; Robbins JB; Rastogi SC
    Infect Immun; 1983 Apr; 40(1):245-56. PubMed ID: 6601061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with Haemophilus influenzae type b-CRM(197) conjugate vaccine elicits a mixed Th1 and Th2 CD(4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody.
    Kamboj KK; King CL; Greenspan NS; Kirchner HL; Schreiber JR
    J Infect Dis; 2001 Oct; 184(7):931-5. PubMed ID: 11528593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trials.
    Sharma HJ; Multani AS; Dutta AK; Joshi SM; Malik S; Bhardwaj S; Chakravarty A; Namjoshi GS; Parekh S; Verma V
    Hum Vaccin; 2009 Jul; 5(7):483-7. PubMed ID: 19395868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer.
    Hamidi A; Verdijk P; Kreeftenberg H
    Hum Vaccin Immunother; 2014; 10(9):2691-6. PubMed ID: 25483504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
    Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
    Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.